Key result
Higher visit-to-visit fasting plasma glucose variability was independently associated with adverse long-term changes in left ventricular mass index (β = 0.227, P < 0.001) and systolic function in patients with type 2 diabetes.
Why the study?
To investigate the effect of visit-to-visit fasting plasma glucose variability on left cardiac structure and function in patients with type 2 diabetes mellitus.
Does visit-to-visit fasting plasma glucose variability predict long-term changes in left cardiac structure and function in patients with type 2 diabetes?
Cohort (n=455)
No
Does visit-to-visit fasting plasma glucose variability predict long-term changes in left cardiac structure and function in patients with type 2 diabetes?
Effect estimate: β = 0.227
p-value: p=<0.001
High visit-to-visit fasting plasma glucose variability is associated with adverse long-term changes in left ventricular structure and systolic function in patients with type 2 diabetes, especially those with suboptimal glycemic control (HbA1c ≥ 7%).
FPG variability may flag higher cardiac remodeling risk in T2DM; leaves open whether stabilizing glucose improves structure or function.
BACKGROUND: To investigate the effect of visit-to-visit fasting plasma glucose (FPG) variability on the left cardiac structure and function in patients with type 2 diabetes mellitus (T2DM). METHODS: In this prospective cohort study, 455 T2DM patients were included and follow-up for a median of 4.7 years. FPG measured on every hospital visit was collected. FPG variability was calculated by its coefficient of variation (CV-FPG). Left cardiac structure and function were assessed using echocardiography at baseline and after follow-up. Multivariable linear regression analyses were used to estimate the effect of FPG variability on the annualized changes in left cardiac structure and function. Subgroup analysis stratified by mean HbA1c levels (< 7% and ≥ 7%) were also performed. RESULT: In multivariable regression analyses, CV-FPG was independently associated with the annualized changes in left ventricle (β = 0.137; P = 0.031), interventricular septum (β = 0.215; P = 0.001), left ventricular posterior wall thickness (β = 0.129; P = 0.048), left ventricular mass index (β = 0.227; P < 0.001), and left ventricular ejection fraction (β = - 0.132; P = 0.030). After additionally stratified by mean HbA1c levels, CV-FPG was still independently associated with the annualized changes in the above parameters in patients with HbA1c ≥ 7%, while not in patients with HbA1c < 7%. CONCLUSIONS: Visit-to-visit variability in FPG could be a novel risk factor for the long-term adverse changes in left cardiac structure and systolic function in patients with type 2 diabetes. Trial registration ClinicalTrials.gov (NCT02587741), October 27, 2015, retrospectively registered.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2019) conducted a cohort in Type 2 diabetes mellitus (n=455). Visit-to-visit fasting plasma glucose variability (CV-FPG) vs. Lower quartiles of CV-FPG was evaluated on Annualized changes in left ventricular mass index (LVMI) (β = 0.227, p=<0.001). Higher visit-to-visit fasting plasma glucose variability was independently associated with adverse long-term changes in left ventricular mass index (β = 0.227, P < 0.001) and systolic function in patients with type 2 diabetes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: